Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
about
Classification Framework and Chemical Biology of Tetracycline-Structure-Based DrugsChemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancersCurrent management of aneurysmal bone cystsDoxycycline alters metabolism and proliferation of human cell linesPaediatric musculoskeletal interventional radiology.The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism.Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.Percutaneous doxycycline treatment of aneurysmal bone cysts with low recurrence rate: a preliminary report.Asymmetric Collagen/chitosan Membrane Containing Minocycline-loaded Chitosan Nanoparticles for Guided Bone Regeneration.Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activationMatrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine.Low concentrations of doxycycline attenuates FasL-induced apoptosis in HeLa cells.Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
P2860
Q27024054-67868CC5-AE59-4B78-A75C-72EADC7DE672Q27694500-634C7DDF-69ED-42D4-8D96-C64750FD6845Q28068662-B8772755-2F0D-4B71-BA7B-F14017DF0CB6Q28533505-973B0AE1-0D6B-493F-837B-FC67E177F7CDQ30366644-606BEFB2-1631-41CE-9227-AB570E333C44Q33714126-1C6B3EDE-5321-4AED-80DE-75AACFB50F1CQ35940473-65B01A40-043C-44B2-86B5-D36C46D3EF5CQ36609555-CA2B7A02-9D78-4923-AEE1-0D0B46DB029BQ36993202-A9FCFD21-819E-46B4-A137-FCE47ED2C436Q37193258-90DCCCB4-F5E9-4D53-A3F0-25D26F732635Q37347935-77536EB7-AD87-4DE2-AA7C-8261A098A70CQ37708436-47B24D56-AA7A-4BFB-8C51-61CEDB6D614EQ38010499-08EBEEF7-A7FF-47EE-A0C8-19FFB3EB426EQ40702253-BA4859C4-8A01-4479-8788-B4456944BB89Q42755979-E8084249-F0E8-42F9-978B-1AB42C971622Q42758736-C4FCB8C5-CBF6-481B-9777-AC968119A596
P2860
Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@ast
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@en
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@nl
type
label
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@ast
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@en
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@nl
prefLabel
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@ast
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@en
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@nl
P2093
P1476
Use of tetracycline as an inhi ...... ne-metastasizing cancer cells.
@en
P2093
Duivenvoorden WC
P304
P577
1997-01-01T00:00:00Z